N6-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming

Theranostics. 2022 Jun 13;12(10):4802-4817. doi: 10.7150/thno.73746. eCollection 2022.

Abstract

Background: Chemoresistance to 5-fluorouracil (5-FU) is a major barrier to influence the treatment efficiency of colorectal cancer (CRC) patients, while the precise molecular mechanisms underlying 5-FU resistance remain to be fully elucidated. Methods: The metabolic profiles including ATP generation, glucose consumption, lactate generation, and oxygen consumption rate (OCR) in 5-FU resistant CRC cells were compared with those in their parental cells. Subsequently, a series of in vitro and in vivo experiments were carried out to investigate the mechanisms responsible for metabolic reprogramming of 5-FU resistant CRC cells. Results: We found that 5-FU resistant CRC cells showed increased levels of ATP generation, glucose consumption, lactate generation, and OCR as compared with those in their parental cells. Further, increased levels of mRNA N6-methyladenosine (m6A) and methyltransferase-like 3 (METTL3) were observed in 5-FU resistant CRC cells. Inhibition or knockdown of METTL3 can suppress glycolysis and restore chemosensitivity of 5-FU resistant CRC cells. Mechanistically, METTL3 enhances the expression of LDHA, which catalyzes the conversion of pyruvate to lactate, to trigger glycolysis and 5-FU resistance. METTL3 can increase the transcription of LDHA via stabilizing mRNA of hypoxia-inducible factor (HIF-1α), further, METTL3 also triggers the translation of LDHA mRNA via methylation of its CDS region and recruitment of YTH domain-containing family protein 1 (YTHDF1). Targeted inhibition of METTL3/LDHA axis can significantly increase the in vitro and in vivo 5-FU sensitivity of CRC cells. Conclusion: Our study indicates that METTL3/LDHA axis-induced glucose metabolism is a potential therapy target to overcome 5-FU resistance in CRC cells.

Keywords: 5-FU; Chemoresistance; Glycolysis; LDHA; METTL3.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Adenosine* / analogs & derivatives
  • Cell Line, Tumor
  • Colorectal Neoplasms* / drug therapy
  • Colorectal Neoplasms* / metabolism
  • Drug Resistance, Neoplasm
  • Fluorouracil* / pharmacology
  • Glucose / metabolism
  • HCT116 Cells
  • Humans
  • L-Lactate Dehydrogenase* / biosynthesis
  • L-Lactate Dehydrogenase* / genetics
  • L-Lactate Dehydrogenase* / metabolism
  • Lactates / metabolism
  • Methyltransferases / genetics
  • RNA, Messenger

Substances

  • Lactates
  • RNA, Messenger
  • Adenosine Triphosphate
  • N-methyladenosine
  • L-Lactate Dehydrogenase
  • LDHA protein, human
  • Methyltransferases
  • METTL3 protein, human
  • Glucose
  • Adenosine
  • Fluorouracil